ReviewCellular and molecular life sciences : CMLS2012
Towards specific NADPH oxidase inhibition by small synthetic peptides.
Review in Cellular and molecular life sciences : CMLS, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Modulation of human neutrophil functions by hydroethanolic cladode extract of Opuntia ficus-indica: an in vitro experimental study.BMC complementary medicine and therapies · 2025Article
- NOX2 As a Target for Drug Development: Indications, Possible Complications, and Progress.Antioxidants & redox signaling · 2015Review
- NOX Modifiers-Just a Step Away from Application in the Therapy of Airway Inflammation?Antioxidants & redox signaling · 2015Review
- Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors.Current pharmaceutical design · 2015Review
- Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis.Current rheumatology reports · 2015Review
- The quest for selective nox inhibitors and therapeutics: challenges, triumphs and pitfalls.Antioxidants & redox signaling · 2014Review
- NADPH oxidases: a perspective on reactive oxygen species production in tumor biology.Antioxidants & redox signaling · 2014Review
- Phagocyte-like NADPH oxidase [Nox2] in cellular dysfunction in models of glucolipotoxicity and diabetes.Biochemical pharmacology · 2014Article
- Supplementation with γ-tocopherol attenuates endotoxin-induced airway neutrophil and mucous cell responses in rats.Free radical biology & medicine · 2014Article
- Intermedin protects against myocardial ischemia-reperfusion injury in diabetic rats.Cardiovascular diabetology · 2013Article
- Article
- NADPH Oxidases NOXs and DUOXs as putative targets for cancer therapy.Anti-cancer agents in medicinal chemistry · 2013Review
- The natural stilbenoid piceatannol decreases activity and accelerates apoptosis of human neutrophils: involvement of protein kinase C.Oxidative medicine and cellular longevity · 2013Article
- Current status of NADPH oxidase research in cardiovascular pharmacology.Vascular health and risk management · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reactive oxygen species (ROS) production by the phagocyte NADPH oxidase is essential for host defenses against pathogens. ROS are very reactive with biological molecules such as lipids, proteins and DNA, potentially resulting in cell dysfunction and tissue insult. Excessive NADPH oxidase activation and ROS overproduction are believed to participate in disorders such as joint, lung, vascular and intestinal inflammation. NADPH oxidase is a complex enzyme composed of six proteins: gp91phox (renamed NOX2), p22phox, p47phox, p67phox, p40phox and Rac1/2. Inhibitors of this enzyme could be beneficial, by limiting ROS production and inappropriate inflammation. A few small non-peptide inhibitors of NADPH oxidase are currently used to inhibit ROS production, but they lack specificity as they inhibit NADPH oxidase homologues or other unrelated enzymes. Peptide inhibitors that target a specific sequence of NADPH oxidase components could be more specific than small molecules. Here we review peptide-based inhibitors, with particular focus on a molecule derived from gp91phox/NOX2 and p47phox, and discuss their possible use as specific phagocyte NADPH oxidase inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.